Navigation Links
Oral Vaccine May Help People With COPD
Date:4/6/2010

Preliminary results suggest a new option to treat the breathing disease

TUESDAY, April 6 (HealthDay News) -- An experimental vaccine for chronic obstructive pulmonary disease (COPD), a progressive respiratory disease that afflicts millions of people, may reduce flare-ups in those with severe forms of the illness, new research finds.

Unlike regular childhood vaccinations or the flu shot, this vaccine, which is made from the bacteria that causes meningitis in children, does not prevent COPD but rather tames the severity, duration and frequency of flare-ups.

"It's not an ideal study but it is suggestive that using this novel oral vaccine can reduce the number of serious COPD exacerbations," said Dr. Norman H. Edelman, chief medical officer of the American Lung Association. "That's a very significant finding and could be a very, very useful tool in the management of severe COPD."

Dr. Len Horovitz, a pulmonary specialist with Lenox Hill Hospital in New York City, added, "they're modest results but certainly favorable and it would seem to be non-toxic."

COPD, which is usually caused by smoking, is the fourth leading cause of death in the United States and, said Edelman, is "a major, major problem."

Currently available treatments include flu and pneumonia shots to prevent infection, and oxygen and medications to improve quality of life. It's unclear if any of these interventions actually prolong life, Edelman said.

"There's not a lot new under the sun," Horovitz said.

Flare-ups of COPD seem to be caused by the wrong bacteria or the wrong proportion of bacteria in the airways, which results in inflammation.

"This [new study] is capitalizing on the theory that the inflammation responses due to colonization of bacteria is different in COPD," Horovitz explained."

The vaccine studied in the new trial, HI-164OV, is made from inactivated Haemophilus influenzae, the bacteria responsible for meningitis in children. The study authors, from Australia, were hoping that this inactivated bacteria would trigger a beneficial change in bacteria colonization.

The trial was a small one, involving only 38 people, all with severe COPD. The patients were randomly selected to receive either the new HI-164OV oral vaccine or a placebo along with best available treatment.

The study showed encouraging results.

Although overall COPD exacerbations only went down by 16 percent, moderate-to-severe exacerbations (those requiring corticosteroids) were reduced by 63 percent. The average length of an exacerbation declined by 37 percent, while antibiotics prescriptions declined 56 percent. And hospitalizations were reduced by 90 percent.

The findings were published in the April issue of the journal Chest.

Many of the study authors reported ties with Hunter Immunology Ltd., an Australian biopharmaceutical company that makes HI-164OV.

More information

The U.S. National Heart, Lung, and Blood Institute has more on COPD.



SOURCES: Norman H. Edelman, M.D., chief medical officer, American Lung Association, Washington, D.C.; Len Horovitz, M.D., pulmonary specialist, Lenox Hill Hospital, New York City; April 2010, Chest


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Genetic Engineering Raises Hope for Lyme Disease Vaccine
2. Only 1 in 4 Americans Got H1N1 Vaccine
3. Clues Found to How Different Flu Vaccines Work
4. GSK Joins Global Vaccine Alliance to Help Prevent Millions of Children from Contracting Pneumococcal Disease in the Worlds Poorest Countries
5. Miles for Hope’s Moving Towards A Cure(SM) Brain Tumor Walk in Boston Raising Funds for Brain Tumor Vaccine and Massachusetts General Hospital
6. FDA Asks Docs to Suspend Using Glaxo Rotavirus Vaccine
7. GlaxoSmithKline Statement on New Information Relating to Manufacture of Rotarix (Rotavirus Vaccine)
8. Keeping up with the neighbors speeds vaccine use
9. Young Kids to Benefit From Broader Pneumococcal Vaccine
10. The Pediatric Dengue Vaccine Initiative Introduces www.DengueWatch.org - a News hub for Tracking Dengue Fever Epidemics Worldwide
11. 1 in 5 At-Risk U.S. Babies Doesnt Get Hepatitis B Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... ... years, Doctors on Liens has published a directory of the top doctors working ... When the company started in 1997, the directory was a single page focusing on chiropractors ... directory features a vast array of medical specialists stretching from Sacramento to San ...
(Date:12/2/2016)... ... December 02, 2016 , ... Center for Autism and ... of those affected by autism spectrum disorder (ASD) and other developmental disabilities. The group, ... will give parents and other caregivers the opportunity to share stories and advice, seek ...
(Date:12/2/2016)... ... December 02, 2016 , ... Mediaplanet’s newest campaign, ... standing as living proof that attitude and determination can combine into the most ... spike around the holidays. This campaign will offer patients a new-found hope, by ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... version of its SaaS LIMS, CloudLIMS Lite. CloudLIMS Lite helps biobanks, clinical, research ... labeling, storing, shipping and disposal. The new version is a faster and a ...
(Date:12/2/2016)... Wexford, PA (PRWEB) , ... December 02, 2016 , ... ... manages stress and overall health, day and night. No other wearable health technology on ... management. We wanted to give poeple more meaningful insights about their health than ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... , Dec. 2, 2016  LifeVac, the revolutionary ... included in the Emergency Response Training and Support Services ... excited to have LifeVac become part of the ERTSS ... Founder and CEO of LifeVac. "Having an established network ... and effectively will help leverage our efforts to spread ...
(Date:12/2/2016)... -- PipelineRx, a leading medication management technology company focused ... its SaaS-based telepharmacy platform, PowerGridRx™ , at ... Clinical Meeting and Exhibition, December 5-7 in ... hospital clients nationally, the Company is a leader ... improve pharmacy operations, enhance patient safety, and reduce ...
(Date:12/2/2016)... 2, 2016  Maxor National Pharmacy Services, LLC ("Maxor"), today ... Inc. ("PSI").  The combination of Texas -based ... -based PSI bring together both company,s clinical expertise and high-touch ... an industry-leading specialty pharmacy. About Maxor ... , , ...
Breaking Medicine Technology: